Identifying patients with gastroesophageal reflux disease - Validation of a practical screening tool

被引:31
作者
Ofman, JJ
Shaw, M
Sadik, K
Grogg, A
Emery, K
Lee, J
Reyes, E
Fullerton, S
机构
[1] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Dept Hlth Serv Res, Los Angeles, CA 90048 USA
[3] Cedars Sinai Med Ctr, Div Gastroenterol, Los Angeles, CA 90048 USA
[4] Zynx Hlth Inc, Los Angeles, CA USA
[5] Janssen Pharmaceutica, Titusville, NJ USA
关键词
gastroesophageal reflux disease; disease management; heartburn; case-finding;
D O I
10.1023/A:1016421401519
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
A reliable, accurate noninvasive method for identifying patients with gastroesophageal reflux disease (GERD) in the primary care setting is needed. A population-based case-finding instrument may assist managed care organizations in identifying candidates for disease management or quality improvement programs. Our aim was to develop and validate a GERD case-finding instrument. A 12-item "GERD Screener" was developed based on literature review and expert opinion with questions about heartburn and regurgitation frequency and severity and medication use, as well demographics and exclusion criteria. Categorical and continuous scoring methods with and without medication use were developed a priori. Using a telephone interview in a medical group, we identified and enrolled 100 subjects with a history of GERD-like symptoms and 103 controls. Each subject completed the GERD Screener, a validated gastrointestinal symptom questionnaire, the Digestive Health Symptom Index (DHSI), and was evaluated independently by two gastroenterologists using a structured format. Agreement by the two physicians that symptoms were consistent with GERD and required an intervention was considered the gold standard. In all, 70 subjects were classified as having GERD and 106 as controls using the gold standard (kappa = 0.73; 95% CI, 0.63-0.82). The scoring method for the screening instrument using a continuous measure of GERD symptoms (frequency and severity) and weighted medication use resulted in an area under ROC of 0.89 (95% CI, 0.84-0.94). Using a cutoff of >9 points, this measure was 83% sensitive and 83% specific. Compared to the gold standard, the DHSI GERD subscale has an area under ROC of 0.89 (95% CI, 0.84-0.94). The GERD Screener was highly correlated with the DHSI GERD subscale, r = 0.78 (95% CI 0.72-0.83; P < 0.0001). In conclusion, the GERD Screener has demonstrated construct, convergent, and predictive validity. It is shorter than existing validated instruments, practical, and easily administered, which may reduce the response and administrative burden. This may serve as a valuable case-finding instrument in primary-care and managed-care organizations wishing to implement programs to improve the quality and efficiency of care.
引用
收藏
页码:1863 / 1869
页数:7
相关论文
共 29 条
[1]  
*AM COLL GASTR, 2000, RICHT SCAL
[2]  
Arthur A, 1999, INT J GERIATR PSYCH, V14, P431, DOI 10.1002/(SICI)1099-1166(199906)14:6<431::AID-GPS937>3.3.CO
[3]  
2-9
[4]   THE RELATION OF GASTROESOPHAGEAL REFLUX DISEASE AND ITS TREATMENT TO ADENOCARCINOMAS OF THE ESOPHAGUS AND GASTRIC CARDIA [J].
CHOW, WH ;
FINKLE, WD ;
MCLAUGHLIN, JK ;
FRANKL, H ;
ZIEL, HK ;
FRAUMENI, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (06) :474-477
[5]  
Corder AP, 1996, BRIT J CLIN PRACT, V50, P245
[6]  
DENTON M, 1997, NEW MED, V1, P123
[8]   Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis [J].
Eggleston, A ;
Wigerinck, A ;
Huijghebaert, S ;
Dubois, D ;
Haycox, A .
GUT, 1998, 42 (01) :13-16
[9]   Evidence-based disease management [J].
Ellrodt, G ;
Cook, DJ ;
Lee, J ;
Cho, M ;
Hunt, D ;
Weingarten, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (20) :1687-1692
[10]   24-HOUR PH MONITORING IN SYMPTOMATIC PATIENTS WITHOUT EROSIVE ESOPHAGITIS WHO DID NOT RESPOND TO ANTIREFLUX TREATMENT [J].
FASS, R ;
MACKEL, C ;
SAMPLINER, RE .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1994, 19 (02) :97-99